Agile Therapeutics Reports Second Quarter 2017 Financial Results
July 28, 2017 07:30 ET
|
Agile Therapeutics, Inc.
Cash Expected to Fund Operations into Q2 2018 FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of December 26, 2017 PRINCETON, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Agile...
Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla®
June 27, 2017 08:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., June 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration...
Agile Therapeutics Reports First Quarter 2017 Financial Results
May 08, 2017 16:11 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 08, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company today reported financial results for the three months ended March 31, 2017, and...
Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists
May 03, 2017 16:15 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company today announced that data from its Phase 3 SECURE study will be presented at...
Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA
April 11, 2017 07:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 11, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, today announced it has received the final meeting minutes from its recent...
Agile Therapeutics Announces a Poster Presentation of its SECURE Phase 3 Study at the Contraceptive Technology 2017 Conference
March 16, 2017 16:30 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, announced a poster presentation of data from the SECURE Phase 3 clinical...
Agile Therapeutics to Present at 29th Annual ROTH Conference
March 01, 2017 16:10 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 01, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company announced today that its Chief Executive Officer, Al...
Agile Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare Conference
February 14, 2017 16:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that its Chief Executive Officer, Al...
Agile Therapeutics to Present at the 2017 BIO CEO & Investor Conference
February 02, 2017 16:15 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that its Chief Executive Officer, Al...
Agile Therapeutics Announces Positive Top-line Phase 3 Results
January 03, 2017 16:11 ET
|
Agile Therapeutics, Inc.
Resubmission of Twirla® New Drug Application Expected to Address FDA’s Complete Response LetterCompany Plans to Resubmit NDA in First Half of...